These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1506807)

  • 1. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour.
    Mathus-Vliegen EM; van de Voorde K; Kok AM; Res AM
    J Intern Med; 1992 Aug; 232(2):119-27. PubMed ID: 1506807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks.
    Drent ML; Zelissen PM; Koppeschaar HP; Nieuwenhuyzen Kruseman AC; Lutterman JA; van der Veen EA
    Int J Obes Relat Metab Disord; 1995 May; 19(5):299-304. PubMed ID: 7647820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
    O'Connor HT; Richman RM; Steinbeck KS; Caterson ID
    Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity.
    Ditschuneit HH; Flechtner-Mors M; Adler G
    J Cardiovasc Risk; 1996 Aug; 3(4):397-403. PubMed ID: 8946272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS
    Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexfenfluramine reduces cardiovascular risk factors.
    Bremer JM; Scott RS; Lintott CJ
    Int J Obes Relat Metab Disord; 1994 Apr; 18(4):199-205. PubMed ID: 8044193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
    Davis R; Faulds D
    Drugs; 1996 Nov; 52(5):696-724. PubMed ID: 9118819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors.
    Swinburn BA; Carmichael HE; Wilson MR
    Int J Obes Relat Metab Disord; 1996 Nov; 20(11):1033-40. PubMed ID: 8923161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexfenfluramine influences dietary compliance and eating behavior, but dietary instruction may overrule its effect on food selection in obese subjects.
    Mathus-Vliegen LM; Res AM
    J Am Diet Assoc; 1993 Oct; 93(10):1163-5. PubMed ID: 8409140
    [No Abstract]   [Full Text] [Related]  

  • 10. Dexfenfluramine. Its place in weight control.
    Turner P
    Drugs; 1990; 39 Suppl 3():53-62. PubMed ID: 2197076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged weight loss with dexfenfluramine treatment in obese patients.
    Finer N; Craddock D; Lavielle R; Keen H
    Diabete Metab; 1987; 13(6):598-602. PubMed ID: 3329122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom.
    Finer N; Craddock D; Lavielle R; Keen H
    Clin Neuropharmacol; 1988; 11 Suppl 1():S179-86. PubMed ID: 3052816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [International study of the effect of dexfenfluramine in obesity (ISIS): 6 months' results].
    Guy-Grand B; Apfelbaum M; Crepaldi G; Gries A; Lefebvre P; Turner P
    Rev Med Interne; 1989; 10(3):271-7. PubMed ID: 2669089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice].
    Geyer G; Haidinger G; Francesconi M; Langmayr N; Prager R; Schoberberger R; Toplak H; von Kalckreuth G; Kunze M
    Acta Med Austriaca; 1995; 22(5):95-101; 104-9. PubMed ID: 8651045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study.
    Lafreniere F; Lambert J; Rasio E; Serri O
    Int J Obes Relat Metab Disord; 1993 Jan; 17(1):25-30. PubMed ID: 8383638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of dexfenfluramine in a weight loss program for obese infertile women.
    Galletly C; Clark A; Tomlinson L
    Int J Eat Disord; 1996 Mar; 19(2):209-12. PubMed ID: 8932560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International trial of long-term dexfenfluramine in obesity.
    Guy-Grand B; Apfelbaum M; Crepaldi G; Gries A; Lefebvre P; Turner P
    Lancet; 1989 Nov; 2(8672):1142-5. PubMed ID: 2572857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity.
    McTavish D; Heel RC
    Drugs; 1992 May; 43(5):713-33. PubMed ID: 1379149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
    Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
    N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged surveillance of dexfenfluramine in severe obesity.
    Mathus-Vliegen EM
    Neth J Med; 1993 Dec; 43(5-6):246-53. PubMed ID: 8107932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.